A detailed history of Quest Partners LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 3,538 shares of JANX stock, worth $177,996. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,538
Previous 5,795 38.95%
Holding current value
$177,996
Previous $243 Million 33.79%
% of portfolio
0.01%
Previous 0.03%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$35.29 - $50.26 $79,649 - $113,436
-2,257 Reduced 38.95%
3,538 $161 Million
Q2 2024

Aug 06, 2024

BUY
$35.12 - $64.78 $153,544 - $283,218
4,372 Added 307.24%
5,795 $243 Million
Q1 2024

May 09, 2024

BUY
$7.93 - $49.75 $11,284 - $70,794
1,423 New
1,423 $53.6 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.1B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.